11 apr: Europa/luk: Nådesløs afstraffelse af Nokia
12 apr: Selskabernes forventninger - torsdag den 12 april
11-04-2012 23:54:00

UPDATE: Quest Diagnostics Names Rusckowski As President, CEO

Relateret indhold

--Quest names Philips executive as new CEO

--Stephen Rusckowski's appointment effective May 1

--Change could mark new course for Quest

(Adds analyst comments, updated share price, other information, in the second, fourth and fifth paragraphs.)

By Anjali Athavaley and Nathalie Tadena

Of DOW JONES NEWSWIRES

NEW YORK -(Dow Jones)- Quest Diagnostics Inc. (DGX) named Royal Philips Electronics NV (PHG, PHIA.AE) executive Stephen Rusckowski as its new president and chief executive, ending a six-month search for a successor to current CEO Surya Mohapatra.

Rusckowski's appointment is effective May 1, and he will join the company's board. Rusckowski has served as CEO of Philips Healthcare, Royal Philips' largest unit, since 2006. During his tenure, revenue at the unit increased to about EUR9 billion and 39% of Royal Philips' total revenue in 2011 from about EUR6B and 21% of revenue in 2005.

The management change could mark a new course for the company. Some decisions Quest made under Mohapatra--such as the acquisition of diagnostics company AmeriPath Inc. and an expansion into India--have been criticized by analysts.

"We knew this was going to get announced any day," said Art Henderson, health-care analyst at Jefferies & Co. "The investment community wasn't sure who the candidate would be. Who they have chosen is obviously somebody who was pretty instrumental in the growth at Philips."

Quest shares rose 1% to $60.20 in after-hours trading Wednesday. The stock is up 2.6% this year.

Quest, the largest diagnostic-testing company in the U.S. by revenue, had been hurt by a decline in doctor-office visits as consumers have reined in their health-care spending since the recession. Last year, the company unveiled a restructuring initiative to reduce its costs by $500 million over the next three years to help it meet profit targets. In October, the company initiated a search for a replacement for Mohapatra, who held the titles of chairman, president and CEO.

Quest also appointed lead director Daniel C. Stanzione as its new non-executive chairman.

"Steve Rusckowski is uniquely qualified to be chief executive officer of Quest Diagnostics," Stanzione said. "He has built an enviable track record in health care by successfully driving growth, both organically and through disciplined, effective acquisitions. His emphasis on operational excellence has enabled him to deliver consistently impressive results."

In January, Quest reported its fourth-quarter earnings rose 14% as the company saw higher testing revenue and improved margins.

-By Anjali Athavaley and Nathalie Tadena, Dow Jones Newswires; 212-416-4912; anjali.athavaley@dowjones.com

(END) Dow Jones Newswires

April 11, 2012 17:54 ET (21:54 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/middag: Vestas som bundprop i nyhedsmættet eliteindeks

17-08-2017 11:41:37
Vestas tager prisen som den mest faldende aktie i C20 Cap torsdag middag, efter at vindmølleselskabet er kommet med regnskab for andet kvartal 2017.Lige efter følger ejendomsservicegiganten ISS, mens GN Store Nord indtager toppen, da regnskaberne fra de to selskaber peger i hver deres retning.Samlet falder eliteindekset torsdag middag med 0,6 pct. til 1159,23, hvilket er billedet i Europa generelt..

Novo/Sydbank: Stærke data med Semaglutid over for rival

17-08-2017 06:59:31
Det er meget stærke data, som medicinalgiganten Novo Nordisk præsenterede onsdag aften fra fase 3-studiet Sustain 7, der sammenligner selskabets middel Semaglutid med ærkerivalen Eli Lillys Trulicity.Det skriver Søren Løntoft Hansen, der er senioranalytiker hos Sydbank, i en kommentar.- Vi ser meget positivt på de efter vores vurdering særdeles stærke Sustain 7-data for Semaglutid over for Trulici..

Coloplast/CEO: Har underskrevet ny VA-kontrakt på trods af fejl

16-08-2017 14:33:48
En fejl i administrationen af kontrakten med det amerikanske veteranministerium, U.S Department of Veterans Affairs, har betydet, at det danske medicoselskab Coloplast vurderer, at det skal tilbagebetale 90 mio. kr. til ministeriet.Selskabets oplyste om engangsbeløbet i regnskabet for tredje kvartal af det forskudte regnskabsår 2016/2017, der blev fremlagt onsdag ved middagstid, og her fremgik det..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas: Stærk ordreindgang er lyspunkt i lidt skuffende regnskab
2
Vestas/ABM: Priserne på nye ordrer er største problem i regnskabet
3
Aktier/tendens: Dugfriske regnskaber vil sætte stemningen
4
Veloxis Q2: Nedjusterer forventninger trods fremgang over hele linjen
5
Coloplast/CEO: Har underskrevet ny VA-kontrakt på trods af fejl

Relaterede aktiekurser

Philips KON 32,09 -0,5% Fald i aktiekurs
Koninklijke Philips N.V... 37,82 1,6% Stigning i aktiekurs
Quest Diagnostics Incorp.. 106,75 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
17. august 2017 13:30:06
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170808.1 - EUROWEB5 - 2017-08-17 13:30:06 - 2017-08-17 13:30:06 - 1 - Website: OKAY